Overview
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence submission.
Last reviewed: 6 October 2021
Next review: We will review this decision if the company decides to make a submission.